Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States

Fonseca, Rafael; Chinaeke, Eric E.; Gupta-Werner, Niodita; Fu, Alex Z.; Kaila, Shuchita

doi:10.1016/j.mayocpiqo.2023.07.001

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its use in induction and consolidation has been widely documented in studies, that evaluated the results of bortezomib, thalidomide and dexamethasone (VTD) with or without daratumumab showed an increase in Minimal Residual Disease negativity of 64% vs 44%in patients who received the quadruplet , this increase translated into a 53% decrease in the risk of progression or death as well as in PFS, with a follow-up of 44.5 months the median PFS had not been reached in the Daratumumab -VTD arm while in the VTD arm was 51.5 months, [7]. the impact was also demonstrated in other study that compared Bortezomib-Lenalidomide-Dexametasone (VRd) versus daratumumab plus VRd, the quadruplet achieve negative MRD in 51% of patients compared to 20.4% in patients in the VRd arm directly impacting PFS al 24 months (95.8 vs 89.8%) [8].…”

Section: Discussionmentioning

confidence: 62%

Daratumumab Post Maintenance after Relapse in Multiple Myeloma

MARTINEZ,

CELAYA,

MUÑIZ

et al. 2024

Preprint

View full text Add to dashboard Cite

We present 4 cases of patients diagnosed with multiple myeloma initially treated without monoclonal antibodies. It was decided to provide the benefit of the drug after maintenance with lenalidomide was initiated to consolidate the post-maintenance response followed by monitoring without any kind of treatment. In this series of 4 cases 100% of the patients achieved a strict complete response with undetectable Minimal Residual Disease (MRD) for flow cytometry after post-maintenance consolidation with daratumumab regardless of the scheme used as induction/consolidation, as well as whether they had received HSCT. Until the last follow-up the patients are under surveillance with no evidence of progression. It should be noted that 3 of 4 of these patients debuted with high-risk disease.

show abstract

Section: Discussionmentioning

confidence: 62%